CNS Pharmaceuticals Company Presentation

CNS pharmaceuticals 13 • CNS has implemented a dual-track drug product manufacturing strategy and engaged U.S.-based Pharmaceutics International, Inc. ("Pii") and Italy-based BSP Pharmaceuticals S.p.A. ("BSP") for the production of Berubicin. • By engaging two separate manufacturers on two separate continents, CNS expects to mitigate COVID-19-related delay risks, diversify its supply chain and provide for localized availability of Berubicin. • CNS completed synthesis of Berubicin active pharmaceutical ingredient (API) and shipped API to both manufacturers to prepare an injectable form of Berubicin for clinical use. • The Company expects drug manufacturing to be completed in coming weeks Berubicin Clinical Drug Supply for U.S. Phase 2 Trial.